Acrivon Therapeutics (NASDAQ:ACRV) Downgraded by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH downgraded shares of Acrivon Therapeutics (NASDAQ:ACRV) from a buy rating to a neutral rating in a report issued on Monday morning, Marketbeat.com reports.

Other analysts have also recently issued research reports about the stock. Piper Sandler lifted their price target on shares of Acrivon Therapeutics from $26.00 to $30.00 and gave the company an overweight rating in a report on Thursday, April 25th. BMO Capital Markets lifted their price target on shares of Acrivon Therapeutics from $18.00 to $25.00 and gave the company an outperform rating in a report on Friday, April 26th. HC Wainwright restated a buy rating and set a $20.00 target price on shares of Acrivon Therapeutics in a report on Thursday, April 25th. Finally, JMP Securities boosted their target price on shares of Acrivon Therapeutics from $14.00 to $17.00 and gave the company a market outperform rating in a report on Thursday, April 25th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of Moderate Buy and a consensus price target of $22.63.

Acrivon Therapeutics Stock Performance

Shares of Acrivon Therapeutics stock opened at $8.23 on Monday. Acrivon Therapeutics has a 52-week low of $3.19 and a 52-week high of $14.30. The stock has a market capitalization of $186.33 million, a price-to-earnings ratio of -3.01 and a beta of 1.94. The company’s 50 day moving average price is $6.87 and its 200-day moving average price is $5.39.

Acrivon Therapeutics (NASDAQ:ACRV) last issued its earnings results on Thursday, March 28th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.14). As a group, equities research analysts forecast that Acrivon Therapeutics will post -3.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Acrivon Therapeutics news, major shareholder Perceptive Advisors Llc bought 2,353,000 shares of the firm’s stock in a transaction on Thursday, April 11th. The stock was acquired at an average price of $8.50 per share, with a total value of $20,000,500.00. Following the transaction, the insider now owns 5,360,858 shares in the company, valued at $45,567,293. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 7.30% of the stock is owned by insiders.

Institutional Investors Weigh In On Acrivon Therapeutics

An institutional investor recently raised its position in Acrivon Therapeutics stock. Exchange Traded Concepts LLC raised its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 34.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 13,289 shares of the company’s stock after purchasing an additional 3,370 shares during the quarter. Exchange Traded Concepts LLC owned 0.06% of Acrivon Therapeutics worth $65,000 as of its most recent SEC filing. 71.62% of the stock is currently owned by institutional investors.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.